Ardelyx Q1 2023 Earnings Report $4.67 +0.01 (+0.21%) (As of 12:04 PM ET) Earnings HistoryForecast Ardelyx EPS ResultsActual EPS-$0.13Consensus EPS -$0.11Beat/MissMissed by -$0.02One Year Ago EPSN/AArdelyx Revenue ResultsActual Revenue$11.37 millionExpected Revenue$10.08 millionBeat/MissBeat by +$1.29 millionYoY Revenue GrowthN/AArdelyx Announcement DetailsQuarterQ1 2023Date5/3/2023TimeN/AConference Call ResourcesConference CallConference Call TranscriptPress ReleaseARDX Earnings HistoryConference Call AudioYour browser does not support the audio element. Listen Now.Powered by Vacuum up cash with these special trades? (Ad)Have you ever heard about a “volatility vacuum?” Most people haven’t. It all revolves around this formula right here. Now, the most important thing is that this equation — when applied to certain tickers at a certain time each month —- can trigger these “volatility vacuums.” And when that happens, anyone has the shot at sucking out payouts of $290, $350, even $1,350 in as little as 24 hours. (With just a $1k starting stake!) Granted, there were smaller wins and those that did not work out but best of all, we can know exactly when these opportunities will hit. I’ve used this info to create a Cash Calendar that lays out the precise dates of these payouts. And I’m sending it for FREE to anyone who joins me during my FREE training right here. Ardelyx Earnings HeadlinesArdelyx, Inc. (NASDAQ:ARDX) Given Consensus Rating of "Moderate Buy" by BrokeragesDecember 12, 2024 | americanbankingnews.comLeerink Partnrs Increases Earnings Estimates for ArdelyxDecember 8, 2024 | americanbankingnews.com"X-Ray Vision" could find thousands of hidden market opportunitiesLet me show you how I trade with “X-Ray vision.” You see, most “trend” traders only use one trend filter when looking for an optimal buy signal. And that can be a big mistake because you can’t see if you’re in a “True Trend.” But my newest trading tool is designed to only target the best, most stable stocks… Using 3 trend filters… which are these green, yellow, and red lines.December 18, 2024 | Jack Carter Trading (Ad)Potential Growth for Ardelyx’s Ibsrela Amidst Market VolatilityDecember 7, 2024 | markets.businessinsider.comArdelyx Lost The Lawsuit, But The Kidney PATIENT Act Will Save ItNovember 24, 2024 | seekingalpha.comArdelyx to Participate at the Piper Sandler 36th Annual Healthcare ConferenceNovember 20, 2024 | globenewswire.comSee More Ardelyx Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Ardelyx? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Ardelyx and other key companies, straight to your email. Email Address About ArdelyxArdelyx (NASDAQ:ARDX), a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation. It also develops XPHOZAH, which is in Phase III clinical trial to reduce serum phosphorus in adults with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia; RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among patients with kidney and/or heart failure; and RDX020, for adult patients with metabolic acidosis, a serious electrolyte disorder. The company has agreements with Kyowa Kirin, Fosun Pharmaceutical Industrial Development Co. Ltd., and Knight Therapeutics, Inc. for the development and commercialization of tenapanor in their respective territories. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.View Ardelyx ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles History Hints at a Rebound for Toll Brothers After EarningsAlibaba Stock: Why Earnings Make It a Buy Despite the Recent DipMercadoLibre Down 23% After Missed Earnings: Time to Buy the Dip?Roblox Stock Soars 22% After Q3 Earnings – A Turning Point Ahead?Apple Earnings - When Really Good Just Isn’t Good Enough Roblox Stock Set for More Gains After Strong Earnings ReportAmazon: Why Analysts Think It's a Solid Buy Ahead of Earnings Upcoming Earnings Cintas (12/19/2024) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
